Ability of fibrinogen γ-derived dodecapeptides with different sequences to bind to rat platelets

Koji Tokutomi, Toshiaki Tagawa, Maki Korenaga, Masatoshi Chiba, Tomohiro Asai, Naohide Watanabe, Shinji Takeoka, Makoto Handa, Yasuo Ikeda, Naoto Oku

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    A dodecapeptide (γ400-411) derived from a fibrinogen γ-chain carboxyl-terminal sequence recognizes specifically the active form of GPIIb/IIIa on the surface of activated platelets. For the purpose of efficient hemostasis, we previously developed ADP-encapsulated liposomes modified with human-dodecapeptide (HHLGGAKQAGDV, human-H12). On the other hand, the amino-acid sequence of H12 from rats is HHMGGSKQVGDM, having only 67% homology to that from humans. Here, we investigated the ability of rat-H12 in comparison with human-H12 to bind to platelets. Firstly, rat platelets were activated with phorbol-12-myristate-13-acetate (PMA), and the activation was confirmed by flow cytometry. Next, we evaluated the dissociation constant (Kd) of human-H12 and rat-H12 for dissociation from rat platelets by using FACS. As a result, the Kd of human-H12 and rat-H12 with respect to rat platelets was 2.78 ± 0.21 and 2.91 ± 0.22 μM, respectively. Furthermore, H12 from both species inhibited quite similarly the aggregation of rat platelets in platelet-rich plasma (PRP). These results suggest that H12 from different species with different amino acid sequences interacts similarly with GPIIb/IIIa on platelets.

    Original languageEnglish
    Pages (from-to)296-301
    Number of pages6
    JournalInternational Journal of Pharmaceutics
    Volume438
    Issue number1-2
    DOIs
    Publication statusPublished - 2012 Nov 15

    Fingerprint

    Fibrinogen
    Blood Platelets
    Amino Acid Sequence
    Platelet-Rich Plasma
    Hemostasis
    Platelet Aggregation
    Liposomes
    Adenosine Diphosphate
    Flow Cytometry
    Acetates

    Keywords

    • Dodecapeptide
    • Fibrinogen
    • GPIIb/IIIa
    • Hemostasis
    • Human
    • Rat

    ASJC Scopus subject areas

    • Pharmaceutical Science

    Cite this

    Ability of fibrinogen γ-derived dodecapeptides with different sequences to bind to rat platelets. / Tokutomi, Koji; Tagawa, Toshiaki; Korenaga, Maki; Chiba, Masatoshi; Asai, Tomohiro; Watanabe, Naohide; Takeoka, Shinji; Handa, Makoto; Ikeda, Yasuo; Oku, Naoto.

    In: International Journal of Pharmaceutics, Vol. 438, No. 1-2, 15.11.2012, p. 296-301.

    Research output: Contribution to journalArticle

    Tokutomi, K, Tagawa, T, Korenaga, M, Chiba, M, Asai, T, Watanabe, N, Takeoka, S, Handa, M, Ikeda, Y & Oku, N 2012, 'Ability of fibrinogen γ-derived dodecapeptides with different sequences to bind to rat platelets', International Journal of Pharmaceutics, vol. 438, no. 1-2, pp. 296-301. https://doi.org/10.1016/j.ijpharm.2012.09.016
    Tokutomi, Koji ; Tagawa, Toshiaki ; Korenaga, Maki ; Chiba, Masatoshi ; Asai, Tomohiro ; Watanabe, Naohide ; Takeoka, Shinji ; Handa, Makoto ; Ikeda, Yasuo ; Oku, Naoto. / Ability of fibrinogen γ-derived dodecapeptides with different sequences to bind to rat platelets. In: International Journal of Pharmaceutics. 2012 ; Vol. 438, No. 1-2. pp. 296-301.
    @article{b121a8e81efe4c34aac521253a280528,
    title = "Ability of fibrinogen γ-derived dodecapeptides with different sequences to bind to rat platelets",
    abstract = "A dodecapeptide (γ400-411) derived from a fibrinogen γ-chain carboxyl-terminal sequence recognizes specifically the active form of GPIIb/IIIa on the surface of activated platelets. For the purpose of efficient hemostasis, we previously developed ADP-encapsulated liposomes modified with human-dodecapeptide (HHLGGAKQAGDV, human-H12). On the other hand, the amino-acid sequence of H12 from rats is HHMGGSKQVGDM, having only 67{\%} homology to that from humans. Here, we investigated the ability of rat-H12 in comparison with human-H12 to bind to platelets. Firstly, rat platelets were activated with phorbol-12-myristate-13-acetate (PMA), and the activation was confirmed by flow cytometry. Next, we evaluated the dissociation constant (Kd) of human-H12 and rat-H12 for dissociation from rat platelets by using FACS. As a result, the Kd of human-H12 and rat-H12 with respect to rat platelets was 2.78 ± 0.21 and 2.91 ± 0.22 μM, respectively. Furthermore, H12 from both species inhibited quite similarly the aggregation of rat platelets in platelet-rich plasma (PRP). These results suggest that H12 from different species with different amino acid sequences interacts similarly with GPIIb/IIIa on platelets.",
    keywords = "Dodecapeptide, Fibrinogen, GPIIb/IIIa, Hemostasis, Human, Rat",
    author = "Koji Tokutomi and Toshiaki Tagawa and Maki Korenaga and Masatoshi Chiba and Tomohiro Asai and Naohide Watanabe and Shinji Takeoka and Makoto Handa and Yasuo Ikeda and Naoto Oku",
    year = "2012",
    month = "11",
    day = "15",
    doi = "10.1016/j.ijpharm.2012.09.016",
    language = "English",
    volume = "438",
    pages = "296--301",
    journal = "International Journal of Pharmaceutics",
    issn = "0378-5173",
    publisher = "Elsevier",
    number = "1-2",

    }

    TY - JOUR

    T1 - Ability of fibrinogen γ-derived dodecapeptides with different sequences to bind to rat platelets

    AU - Tokutomi, Koji

    AU - Tagawa, Toshiaki

    AU - Korenaga, Maki

    AU - Chiba, Masatoshi

    AU - Asai, Tomohiro

    AU - Watanabe, Naohide

    AU - Takeoka, Shinji

    AU - Handa, Makoto

    AU - Ikeda, Yasuo

    AU - Oku, Naoto

    PY - 2012/11/15

    Y1 - 2012/11/15

    N2 - A dodecapeptide (γ400-411) derived from a fibrinogen γ-chain carboxyl-terminal sequence recognizes specifically the active form of GPIIb/IIIa on the surface of activated platelets. For the purpose of efficient hemostasis, we previously developed ADP-encapsulated liposomes modified with human-dodecapeptide (HHLGGAKQAGDV, human-H12). On the other hand, the amino-acid sequence of H12 from rats is HHMGGSKQVGDM, having only 67% homology to that from humans. Here, we investigated the ability of rat-H12 in comparison with human-H12 to bind to platelets. Firstly, rat platelets were activated with phorbol-12-myristate-13-acetate (PMA), and the activation was confirmed by flow cytometry. Next, we evaluated the dissociation constant (Kd) of human-H12 and rat-H12 for dissociation from rat platelets by using FACS. As a result, the Kd of human-H12 and rat-H12 with respect to rat platelets was 2.78 ± 0.21 and 2.91 ± 0.22 μM, respectively. Furthermore, H12 from both species inhibited quite similarly the aggregation of rat platelets in platelet-rich plasma (PRP). These results suggest that H12 from different species with different amino acid sequences interacts similarly with GPIIb/IIIa on platelets.

    AB - A dodecapeptide (γ400-411) derived from a fibrinogen γ-chain carboxyl-terminal sequence recognizes specifically the active form of GPIIb/IIIa on the surface of activated platelets. For the purpose of efficient hemostasis, we previously developed ADP-encapsulated liposomes modified with human-dodecapeptide (HHLGGAKQAGDV, human-H12). On the other hand, the amino-acid sequence of H12 from rats is HHMGGSKQVGDM, having only 67% homology to that from humans. Here, we investigated the ability of rat-H12 in comparison with human-H12 to bind to platelets. Firstly, rat platelets were activated with phorbol-12-myristate-13-acetate (PMA), and the activation was confirmed by flow cytometry. Next, we evaluated the dissociation constant (Kd) of human-H12 and rat-H12 for dissociation from rat platelets by using FACS. As a result, the Kd of human-H12 and rat-H12 with respect to rat platelets was 2.78 ± 0.21 and 2.91 ± 0.22 μM, respectively. Furthermore, H12 from both species inhibited quite similarly the aggregation of rat platelets in platelet-rich plasma (PRP). These results suggest that H12 from different species with different amino acid sequences interacts similarly with GPIIb/IIIa on platelets.

    KW - Dodecapeptide

    KW - Fibrinogen

    KW - GPIIb/IIIa

    KW - Hemostasis

    KW - Human

    KW - Rat

    UR - http://www.scopus.com/inward/record.url?scp=84867401098&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84867401098&partnerID=8YFLogxK

    U2 - 10.1016/j.ijpharm.2012.09.016

    DO - 10.1016/j.ijpharm.2012.09.016

    M3 - Article

    VL - 438

    SP - 296

    EP - 301

    JO - International Journal of Pharmaceutics

    JF - International Journal of Pharmaceutics

    SN - 0378-5173

    IS - 1-2

    ER -